By Puyaan Singh and Bhanvi Satija Sept 11 (Reuters) - GSK said on Friday it will be shutting down a vaccine factory in ...

GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.  | GSK is ...

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid ...

GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. This advancement is supported by positive results from a phase II ...

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at ...

GSK’s mRNA flu vaccine enters Phase III after positive results, putting the drugmaker closer to competing with Moderna in the evolving flu vaccine market.

GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid what a spokesperson said is ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the ...

GSK has announced that Japan’s Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of ...

Please provide your email address to receive an email when new articles are posted on . Penmenvy protects against meningococcal serotypes A, B, C, W and Y. CDC vaccine advisors are set to discuss ...

GSK’s growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV’s long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma ...

The Trump administration's apparent vaccine skepticism and proposed tariffs on Pharma could significantly impact GSK plc's vaccine division and its overall profitability, despite CEO Walmsley's ...